Literature DB >> 29063509

Erratum to: Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM).

Mihoko Matsumura1, Yuki Nakatani2,3, Seiichi Tanka2, Chie Aoki2, Masaaki Sagara2, Kazunori Yanagi2, Kunihiro Suzuki2, Yoshimasa Aso2.   

Abstract

Unfortunately, the original publication of this paper contained errors in the presentation of Fig. 2.

Entities:  

Year:  2017        PMID: 29063509      PMCID: PMC5688979          DOI: 10.1007/s13300-017-0308-x

Source DB:  PubMed          Journal:  Diabetes Ther            Impact factor:   2.945


Erratum to: Diabetes Ther (2017) 8:821–827 DOI 10.1007/s13300-017-0274-3

Unfortunately, the original publication of this paper contained errors in the presentation of Fig. 2. The corrected Fig. 2 is given below.
Fig. 2

The total amount of insulin in all patients was divided into basal and bolus regimens to show changes from days 1 to 7. The number of basal insulin units decreased from 128 to 76 and that of bolus insulin from 266 to 154

The total amount of insulin in all patients was divided into basal and bolus regimens to show changes from days 1 to 7. The number of basal insulin units decreased from 128 to 76 and that of bolus insulin from 266 to 154
  1 in total

1.  Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor.

Authors:  Viktor Rotbain Curovic; Morten B Houlind; Tine W Hansen; Jesper Eugen-Olsen; Jens Christian Laursen; Mie K Eickhoff; Frederik Persson; Peter Rossing
Journal:  Front Pharmacol       Date:  2022-04-27       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.